ADDIA consortium is coordinated by Amoneta Diagnostics S.A.S., a French SME developing biomarker-based diagnostic

products for neurodegenerative diseases. For more information on Amoneta, visit www.amoneta-diagnostics.com

Firalis S.A. is the parent company of Amoneta Diagnostics S.A.S. and a participant of ADDIA project. Firalis is a leader SME in biomarker R&D, developing innovative diagnostic solutions, in particular for cardiovascular diseases and toxicities.
For more information on Firalis, please visit www.firalis.com

The ADDIA Consortium, started in Aug-2015 and funded by the E.C. within the franework of Horizon-2020/PHC-12 program, is conducting an observational multicenter Proof-of-Performance (PoP) clinical trial, in participation of the following clinical research centers: 

• The University Hospital of Strasbourg, Strasbourg/FR,
  Dr. Frédéric BLANC
• The Colmar Hospital, Colmar/FR,
  Dr. François SELLAL
• The Leenaards Memory Center, Lausanne/CH, 
  Centre Hospitalier Universitaire Vaudois (CHUV)
  Prof. Jean-François DEMONET
• National Alzheimer's Center, Brescia/IT,
  Dr. Moira MARIZZONI

• Assistance Publique - Hôpitaux de Paris (AP-HP), Paris/FR
  Prof. Bruno DUBOIS
• Istanbul Faculty of Medicine,
  Department of Neurology, İstanbul/TR,
  Prof. Dr. Hakan GÜRVİT
• Hôpital Roger Salengro, Lille/FR
  Centre Hospitalier Régional Universitaire (CHRU)
  Pr. Florence PASQUIER
   
• Cliniques Universitaires Saint Luc, Brussels/BE
  Université Catholique de Louvain (UCL)
  Pr. Adrian IVANOIU
   
• Hôpitaux Universitaires de Genève, Geneva/CH
  Pr. Giovanni B. FRISONI
  
  NEW SITES THAT JOINED IN THE CLINICAL STUDY WITHIN 2018 :
   
• Hôpital Erasme, Brussels/BE
  Cliniques Universitaires de Bruxelles (CUB)
  Dr. Jean-Christophe BIER
   
• Hôpital Jean Minjoz, Besançon/FR
  CHRU de Besançon
  Dr. Eloi MAGNIN
   
• Hôpital Gui de Chauliac, Montpellier/FR
  CHU de Montpellier
  Dr. Audrey GABELLE
   
• lnstitut Claude Pompidou, Nice/FR
  CHU de Nice
  Dr. Renaud DAVID

For more information, do not hesitate to contact us.